STOCK TITAN

NewGenIvf closes stock offering, grossing about $2.5M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

NewGenIvf Group Limited (NIVF) closed a firm-commitment offering with approximately $2.5 million in gross proceeds, before discounts and expenses. It issued 9,501,148 Class A ordinary shares and pre-funded warrants for up to 61,927,422 shares, priced at $0.035 per share and $0.03499 per warrant; the warrants are immediately exercisable at $0.00001 per share.

The company expects to use net proceeds, together with existing cash, for commercialization and expansion of Nodexus advanced cytometry and assisted reproductive services, strategic investments in prediction-market and digital-asset/AI initiatives, UAE real estate interests, and general corporate purposes. Management retains broad discretion. Approximately $625,000 of gross proceeds was applied to repurchase and cancel $584,112 of Exchange Note principal; the Holder reduced by $625,000 the cash purchase price otherwise payable for securities at closing.

A limited waiver changes one Exchange Note conversion-price clause to 76% of the lowest daily VWAP over seven consecutive Trading Days before a Conversion Notice, during the 10th through 70th Trading Days after the offering announcement. It takes effect after both parties execute and deliver it and the company pays the $15,000 legal-fee reimbursement.

Filing Explained

The closed offering’s 9% underwriting discount and counsel-fee reimbursement capped at $80,000 reduce net proceeds below roughly $2.5 million gross.

The offering closed on November 20: issued shares have increased the share count, while exercising the pre-funded warrants would add shares and further reduce existing holders’ percentage ownership.

Officers and directors who held ordinary shares agreed, subject to customary exceptions, not to offer, sell, or otherwise dispose of their covered shares for 60 days after closing.

Gross proceeds Approximately $2.5 million Offering proceeds before underwriting discounts and other offering expenses
Class A ordinary shares issued 9,501,148 shares At the November 20, 2026 offering closing
Shares underlying pre-funded warrants Up to 61,927,422 shares At the offering closing
Offering price per Class A ordinary share $0.035 Offering price
Offering price per pre-funded warrant $0.03499 Offering price
Pre-funded warrant exercise price $0.00001 per Class A ordinary share Exercise price
Exchange Note principal repurchased $584,112 Repurchased at the offering closing
Alternate Conversion Price clause 76% of the lowest daily VWAP Specified Exchange Note clause during the Waiver Period
firm commitment financial
"underwritten offering made on a firm commitment basis"
An underwriting agreement where an investment bank guarantees to buy an entire new issue of securities from an issuer and then resell them to the public. Think of it as a store owner agreeing to buy a whole shipment upfront so the seller gets paid immediately; for investors this matters because it reduces the risk that the offering will fail, sets the initial supply and price pressure in the market, and signals underwriter confidence in selling the shares.
Pre-Funded Warrants financial
"pre-funded warrants to purchase up to 61,927,422 Class A Ordinary Shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
volume-weighted average price financial
"lowest daily volume-weighted average price (VWAP)"
Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.
Alternate Conversion Price financial
"definition of “Alternate Conversion Price”"
Waiver Period financial
"during the period ... (the “Waiver Period”)"
underwriting discount financial
"underwriting discount equal to 9.0% of the gross proceeds"
The underwriting discount is the fee that investment banks or broker-dealers keep when they buy securities from an issuer and resell them to the public; it’s the difference between the price paid to the company and the public offering price, shown per share or as a percentage. It matters to investors because it reduces the cash the company actually raises and is a cost built into the deal—like a sales commission—so a larger discount can mean higher issuance costs, tighter returns for new investors, and a signal about how much effort underwriters must expend to sell the offering.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NIVF shares and pre-funded warrants were included at closing?

The closing included 9,501,148 Class A ordinary shares and warrants for up to 61,927,422 shares. The offering price was $0.035 per share and $0.03499 per warrant; each warrant has a $0.00001 exercise price.

How much did NIVF raise and how does it expect to use the proceeds?

The offering generated approximately $2.5 million in gross proceeds before underwriting discounts and other offering expenses. The company expects to use net proceeds, together with existing cash, for Nodexus advanced cytometry and assisted reproductive services, strategic investments in prediction-market and digital-asset/AI initiatives, UAE real estate interests, and general corporate purposes.

How does the NIVF Exchange Note repurchase work?

The company repurchased $584,112 of Exchange Note principal for a $625,000 purchase price. Rather than paying the Holder directly, the company directed a $625,000 reduction in the cash price the Holder otherwise owed for securities at closing; the repurchased principal was cancelled. The stated balance was $5,769,469 before and $5,185,357 after the repurchase.

What did NIVF's Exchange Note waiver change?

The waiver sets one conversion-price clause at 76% of the lowest daily VWAP over seven consecutive Trading Days ending immediately before delivery or deemed delivery of a Conversion Notice. The Waiver Period runs from the 10th through the 70th Trading Day after the offering announcement. The agreement becomes effective upon execution and delivery by both parties and payment in full of the $15,000 legal-fee reimbursement.

What restrictions did NIVF officers and directors accept?

Officers and directors holding ordinary shares agreed to 60-day post-closing lockups, subject to customary exceptions. They agreed not to offer, sell, or otherwise dispose of ordinary shares they beneficially owned during that period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission File Number: 001-42004

 

NEWGENIVF GROUP LIMITED

(Exact name of registrant as specified in its charter)

 

36/39-36/40, 13th Floor, PS Tower

Sukhumvit 21 Road (Asoke)

Khlong Toei Nuea Sub-district

Watthana District, Bangkok 10110

Thailand

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒     Form 40-F ☐

 

 

 

 

 

EXPLANATORY NOTE

 

Underwritten Offering

 

Underwriting Agreement

 

On November 19, 2026, NewGenIvf Group Limited (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Aegis Capital Corp. (“Aegis”), pursuant to which Aegis acted as the sole book-running manager and underwriter for an underwritten offering made on a firm commitment basis (the “Offering”). The Company agreed to pay Aegis an underwriting discount equal to 9.0% of the gross proceeds of the Offering and to reimburse Aegis for certain expenses, including the fees and disbursements of its counsel of up to $80,000. The Underwriting Agreement contains customary representations, warranties, and indemnification provisions.

 

On November 20, 2026, the Company closed the Offering and issued (i) 9,501,148 Class A ordinary shares with no par value (the “Class A Ordinary Shares”) (including 8,350,578 Class A Ordinary Shares issued upon the pre-closing exercise of pre-funded warrants) and (ii) pre-funded warrants to purchase up to 61,927,422 Class A Ordinary Shares (the “Pre-Funded Warrants”), representing an aggregate of 71,428,570 Class A Ordinary Shares issued or underlying the Pre-Funded Warrants. The offering price was $0.035 per Class A Ordinary Share and $0.03499 per Pre-Funded Warrant, and the exercise price of each Pre-Funded Warrant is $0.00001 per Class A Ordinary Share. The aggregate gross proceeds to the Company were approximately $2.5 million, before deducting underwriting discounts and commissions and offering expenses. The Company expects to use the net proceeds from the Offering, together with its existing cash, for commercialization and expansion of the Nodexus advanced cytometry technology and its assisted reproductive services platform, further strategic investments in prediction-market and digital-asset/AI initiatives, its real estate interests in the UAE, and other general corporate purposes. The Company’s management will retain broad discretion to apply these net proceeds. The Company will also apply approximately $625,000 of the gross proceeds of this Offering to repurchase $584,112 in principal amount of the Exchange Note as described below.

  

The Class A Ordinary Shares and Pre-Funded Warrants were issued pursuant to an effective shelf registration statement on Form F-3 (No. 333-299649) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on November 12, 2026. A final prospectus supplement and accompanying prospectus describing the terms of the Offering were filed with the SEC on November 20, 2026.

 

Lock-Up Agreements

 

Concurrently with the execution of the Underwriting Agreement, the Company’s officers and directors holding the Company’s ordinary shares entered into lock-up agreements (the “Lock-Up Agreements”) pursuant to which they agreed, subject to customary exceptions, not to offer, sell, or otherwise dispose of any ordinary shares beneficially owned by them for sixty (60) days following the closing of the Offering.

 

Press Release

 

The Company announced the pricing of the Offering in a press release issued on November 19, 2026, which is furnished as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.

 

The Company announced the closing of the Offering in a press release issued on November 20, 2026, which is furnished as Exhibit 99.2 to this Report on Form 6-K and incorporated herein by reference.

 

1

 

 

Limited Waiver and Repurchase Agreement

 

On November 19, 2026, the Company entered into a Limited Waiver and Repurchase Agreement (the “Waiver Agreement”) with the holder (the “Holder”) of the Company's outstanding senior convertible note issued pursuant to an Amendment and Exchange Agreement dated August 11, 2026 (the “Exchange Note”). The Waiver Agreement relates to the Offering.

 

Limited Waiver

 

Under the Waiver Agreement, the Holder agreed to a one-time, limited waiver of a portion of the definition of “Alternate Conversion Price” in Section 32(g) of the Exchange Note. During the period beginning on the tenth Trading Day (as defined in the Exchange Note) after the public announcement of the Offering and ending on and including the seventieth Trading Day after that announcement (the “Waiver Period”), clause (y) of Section 32(g) of the Exchange Note will be deemed to equal 76% of the lowest daily volume-weighted average price (“VWAP”) during the seven consecutive Trading Days ending on and including the Trading Day immediately preceding delivery or deemed delivery of the applicable Conversion Notice. “Trading Day” and “Conversion Notice” have the meanings assigned in the Exchange Note. The limited waiver modifies only the specified clause during the Waiver Period and does not replace the entire definition of Alternate Conversion Price. Except as expressly provided in the Waiver Agreement, the existing transaction and exchange documents remain in full force and effect. The limited waiver does not constitute a waiver of other matters or a commitment to grant future waivers.

 

The Waiver Agreement provides that it becomes effective upon the later of execution and delivery by both parties and the Company's payment in full of the agreed Waiver Legal Fee Reimbursement (as defined below).

 

Mandatory Repurchase

 

Under the Waiver Agreement, simultaneously with the initial closing of the Offering, the Company is required to repurchase $584,112 of the outstanding principal of the Exchange Note for a repurchase price of $625,000. Rather than paying that amount directly to the Holder, the Company has directed the Holder to reduce by $625,000 the cash purchase price otherwise payable by the Holder for securities it acquires at the initial closing of the Offering. The repurchased portion of the Exchange Note is automatically cancelled upon completion of the repurchase.

 

The Waiver Agreement states that the outstanding principal balance of the Exchange Note immediately before the Offering is $5,769,469 and that, after giving effect to the repurchase described above, the outstanding principal balance will be $5,185,357.

 

The Company also agreed to reimburse the Holder's counsel a non-accountable amount of $15,000 for costs and expenses incurred in drafting and negotiating the Waiver Agreement (the “Waiver Legal Fee Reimbursement”).

 

The foregoing descriptions of the Underwriting Agreement, the Pre-Funded Warrants, the Lock-Up Agreements and the Waiver Agreement are qualified in their entirety by reference to the full text of the form of each of the Underwriting Agreement, the Pre-Funded Warrant, the Lock-Up Agreement and the Waiver Agreement, attached to this report as Exhibits 1.1, 4.1, 10.1 and 10.2, respectively, and incorporated herein by reference.

 

This Report on Form 6-K shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the securities described herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

 

2

 

 

Forward-Looking Statements

 

This Report on Form 6-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. securities laws. Forward-looking statements are based on the Company’s current expectations, beliefs and assumptions regarding future events and performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “expect,” “plan,” “intend,” “estimate,” or “continue,” or the negatives of these terms or other comparable terminology.

 

Forward-looking statements in this Report on Form 6-K include, among other things, statements about the intended use of the net proceeds of the Offering. These forward-looking statements are subject to risks, uncertainties, and assumptions that are difficult to predict. Actual results may differ materially from those expressed or implied in the forward-looking statements. Factors that could cause such differences include, but are not limited to, market conditions, the Company’s ability to deploy the net proceeds as currently contemplated, and other risks described in the Company’s filings with the SEC.

 

The Company undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by applicable law.

 

EXHIBIT INDEX

 

Exhibit No.   Description
1.1   Form of Underwriting Agreement
4.1   Form of Pre-Funded Warrant
10.1   Form of Lock-Up Agreement
10.2   Form of Limited Waiver and Repurchase Agreement
99.1   Press Release, dated November 19, 2026
99.2   Press Release, dated November 20, 2026

 

3

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: November 20, 2026

 

  NEWGENIVF GROUP LIMITED
     
  By: /s/ Wing Fung Alfred Siu
  Name: Wing Fung Alfred Siu
  Title: Chairman of the Board and Director

 

 

4

 

Exhibit 99.1

 

NewGenIvf Group Limited Announces Pricing of $2.5 Million Underwritten Offering

 

BANGKOK, November 19, 2026 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (the “Company”), a technology-driven, diversified growth company, today announced the pricing of a firm commitment underwritten offering with gross proceeds to the Company expected to be approximately $2.5 million, before deducting underwriting fees and other offering expenses payable by the Company.

 

The offering consists of 71,428,570 Class A Ordinary Shares (or Pre-Funded Warrants in lieu thereof). The offering price per Class A Ordinary Share is $0.035 (or $0.03499 for each Pre-Funded Warrant, which is equal to the offering price per Class A Ordinary Share to be sold in the offering minus an exercise price of $0.00001 per Pre-Funded Warrant). The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full. For each Pre-Funded Warrant sold in the offering, the number of Class A Ordinary Shares in the offering will be decreased on a one-for-one basis.

 

Aggregate gross proceeds to the Company are expected to be approximately $2.5 million. The transaction is expected to close on or about November 20, 2026, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital.

 

Aegis Capital Corp. is acting as the sole book-running manager for the offering. Han Kun Law Offices LLP is acting as U.S. counsel to the Company. Kaufman & Canoles, P.C. is acting as U.S. counsel to Aegis Capital Corp.

 

The offering is being made pursuant to an effective shelf registration statement on Form F-3 (No. 333-299649) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on November 12, 2026. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010.

 

Interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.

 

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

 

 

About NewGenIvf Group Limited

 

NewGenIvf Group Limited is a technology-forward, diversified growth company pursuing opportunities across real estate development, digital asset innovation, and reproductive health solutions. The Company operates through NewGenProperty, focused on real estate development projects in Ras Al Khaimah, United Arab Emirates; NewGenDigital, focused on digital asset and decentralized-finance solutions; and NewGenSup, focused on health and longevity products and solutions. NewGenIVF’s legacy business includes IVF and assisted reproductive treatment services across Asia. To learn more, visit www.nivf.global. Information contained on, or accessible through, the Company’s website is not incorporated by reference into this press release.

 

Forward-Looking Statements

 

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

 

ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email: Newgenivf.IR@icrinc.com

 

 

 

Exhibit 99.2

 

NewGenIvf Group Limited Announces Closing of $2.5 Million Underwritten Offering

 

BANGKOK, November 20, 2026 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (the “Company”), a technology-driven, diversified growth company, today announced the closing of its previously announced firm commitment underwritten offering with gross proceeds to the Company of approximately $2.5 million, before deducting underwriting fees and other offering expenses payable by the Company.

 

The offering consisted of 71,428,570 Class A Ordinary Shares (or pre-funded warrants to purchase Class A Ordinary Shares in lieu thereof (the “Pre-Funded Warrants”)). At closing, the offering comprised 9,501,148 Class A Ordinary Shares and Pre-Funded Warrants to purchase up to 61,927,422 Class A Ordinary Shares. The offering price per Class A Ordinary Share was $0.035 (or $0.03499 for each Pre-Funded Warrant, which is equal to the offering price per Class A Ordinary Share sold in the offering minus an exercise price of $0.00001 per Pre-Funded Warrant). The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until exercised in full. For each Pre-Funded Warrant sold in the offering, the number of Class A Ordinary Shares in the offering will be decreased on a one-for-one basis.

 

Aggregate gross proceeds to the Company were approximately $2.5 million. The transaction closed on November 20, 2026. The Company expects to use the net proceeds from the offering, together with its existing cash, for commercialization and expansion of the Nodexus advanced cytometry technology and our assisted reproductive services platform, further strategic investments in prediction-market and digital-asset/AI initiatives, our real estate interests in the UAE, and other general corporate purposes. Our management will retain broad discretion to apply these net proceeds. We will also apply approximately $625,000 of the gross proceeds of this offering to repurchase $584,112 in principal amount of the Exchange Note. The Company’s Class A Ordinary Shares are listed on the Nasdaq Capital Market under the symbol “NIVF”.

 

Aegis Capital Corp. acted as the sole book-running manager for the offering. Han Kun Law Offices LLP acted as U.S. counsel to the Company. Kaufman & Canoles, P.C. acted as U.S. counsel to Aegis Capital Corp.

 

The offering was made pursuant to an effective shelf registration statement on Form F-3 (No. 333-299649) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on November 12, 2026. A final prospectus supplement and accompanying prospectus describing the terms of the offering have been filed with the SEC and are available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010.

 

Interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and the offering.

 

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

 

 

 

About NewGenIvf Group Limited

 

NewGenIvf Group Limited is a technology-forward, diversified growth company pursuing opportunities across real estate development, digital asset innovation, and reproductive health solutions. The Company operates through NewGenProperty, focused on real estate development projects in Ras Al Khaimah, United Arab Emirates; NewGenDigital, focused on digital asset and decentralized-finance solutions; and NewGenSup, focused on health and longevity products and solutions. The Company’s legacy business includes IVF and assisted reproductive treatment services across Asia. To learn more, visit www.nivf.global. Information contained on, or accessible through, the Company’s website is not incorporated by reference into this press release.

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the anticipated use of proceeds from the offering, the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. For a discussion of the risks and uncertainties that could cause actual results to differ materially, see the section entitled “Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025 and in the final prospectus supplement relating to the offering. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

 

Investor Contact:

 

ICR, LLC

Robin Yang

Phone: +1 (212) 537-4406

Email: Newgenivf.IR@icrinc.com

 

 

 

Filing Exhibits & Attachments

6 documents

Keep reading